Given the relevance of Myeloid Cell Leukemia-1 (Mcl-1), a pro-survival BCL-2 family protein in AML pathogenesis and drug resistance, it represents an attractive target for therapeutic intervention (Nix & Price 2019; Tanaka et al. 2013). Here, BCL2 is linked to acute myeloid leukemia.